(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 10.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.31%.
Innoviva's revenue in 2026 is $388,521,000.On average, 6 Wall Street analysts forecast INVA's revenue for 2026 to be $32,974,651,723, with the lowest INVA revenue forecast at $30,952,896,287, and the highest INVA revenue forecast at $34,560,503,528. On average, 5 Wall Street analysts forecast INVA's revenue for 2027 to be $35,621,476,518, with the lowest INVA revenue forecast at $32,860,255,058, and the highest INVA revenue forecast at $39,269,459,053.
In 2028, INVA is forecast to generate $39,628,350,551 in revenue, with the lowest revenue forecast at $34,001,978,635 and the highest revenue forecast at $45,157,522,686.